PL1803441T3 - Farmaceutyczne formulacje fenofibratu o polepszonej biodostępności - Google Patents

Farmaceutyczne formulacje fenofibratu o polepszonej biodostępności

Info

Publication number
PL1803441T3
PL1803441T3 PL05258082T PL05258082T PL1803441T3 PL 1803441 T3 PL1803441 T3 PL 1803441T3 PL 05258082 T PL05258082 T PL 05258082T PL 05258082 T PL05258082 T PL 05258082T PL 1803441 T3 PL1803441 T3 PL 1803441T3
Authority
PL
Poland
Prior art keywords
fenofibrate
pharmaceutical formulations
improved bioavailability
polethylene
polyethylene glycol
Prior art date
Application number
PL05258082T
Other languages
English (en)
Inventor
Itzhak E Lerner
Vered Rosenberger
Moshe Flashner-Barak
Anna Drabkin
Naomi Moldavski
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PL1803441T3 publication Critical patent/PL1803441T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL05258082T 2005-12-28 2005-12-28 Farmaceutyczne formulacje fenofibratu o polepszonej biodostępności PL1803441T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05258082A EP1803441B1 (en) 2005-12-28 2005-12-28 Pharmaceutical formulations of fenofibrate having improved bioavailability

Publications (1)

Publication Number Publication Date
PL1803441T3 true PL1803441T3 (pl) 2009-10-30

Family

ID=36260529

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05258082T PL1803441T3 (pl) 2005-12-28 2005-12-28 Farmaceutyczne formulacje fenofibratu o polepszonej biodostępności

Country Status (7)

Country Link
EP (1) EP1803441B1 (pl)
AT (1) ATE429902T1 (pl)
DE (1) DE602005014258D1 (pl)
DK (1) DK1803441T3 (pl)
ES (1) ES2325450T3 (pl)
PL (1) PL1803441T3 (pl)
PT (1) PT1803441E (pl)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
FR2730231B1 (fr) 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
FR2737121B1 (fr) 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6814977B1 (en) 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6719999B2 (en) 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
EP1322289B1 (en) * 2000-09-20 2007-07-25 Jagotec AG Spray drying process of compositions containing fenofibrate
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
IL164152A0 (en) 2002-03-26 2005-12-18 Teva Pharma Drug microparticles
KR20130103818A (ko) * 2003-10-10 2013-09-24 벨로시스 파마슈티컬스 에이/에스 피브레이트를 포함하는 고형 제제

Also Published As

Publication number Publication date
ES2325450T3 (es) 2009-09-04
DK1803441T3 (da) 2009-08-03
PT1803441E (pt) 2009-06-08
EP1803441A1 (en) 2007-07-04
HK1104790A1 (en) 2008-01-25
DE602005014258D1 (de) 2009-06-10
EP1803441B1 (en) 2009-04-29
ATE429902T1 (de) 2009-05-15

Similar Documents

Publication Publication Date Title
WO2005020913A3 (en) Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
WO2006128693A3 (en) 2 -oxo-i -pyrrolidine derivatives/ processes for preparing them and their therapeutic use on the central nervous system
SI2415484T1 (sl) Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
TW200716206A (en) Unitary pharmaceutical dosage form
AP2405A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms.
MX2009006917A (es) Agentes para combatir parasitos en animales.
TWI268278B (en) 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses
ZA200608029B (en) Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
WO2007021970A3 (en) Stable pharmaceutical formulations and methods of use thereof
TW200716605A (en) 2,6-quinolinyl derivatives, processes for preparing them and their uses
TW200731991A (en) Lipophilic di(anticancer drug) compounds, compositions and related methods
BRPI0410044A (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
WO2007065595A3 (en) Xanthine derivatives, processes for preparing them and their uses
IL174655A0 (en) Drug containing (2r)-2-propyloctanoic acid as the active ingredient
BRPI0520821A2 (pt) formulações farmacêuticas de fenofibrato com biodisponibilidade melhorada
WO2004064757A3 (en) Absorption enhancing agents
TW200716618A (en) Chemical compounds
WO2006072070A3 (en) Pharmaceutical formulations of gallium salts
TW200718698A (en) Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
PT1803441E (pt) Formulações farmacêuticas de fenofibrato com biodisponibilidade melhorada
TW200731964A (en) Pharmaceutical formulations of fenofibrate having improved bioavailability
TW200731990A (en) Lipophilic anticancer drug compounds, compositions, and related methods
PT1720540E (pt) Métodos de tratamento de tumores resistentes ou refractários
SE0203817D0 (sv) New composition